|Articles|July 28, 2009
Retina Roundtable Session 3
Advertisement
Subscribe
In this third session, the physicians discuss how they communicate to their patients the increased risk of stroke that may be associated with dosing of anti-VEGF agents.
Participants include:
Return to
Return to
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA accepts resubmitted ONS-5010 BLA from Outlook Therapeutics
2
STAAR Surgical announces amendments to Alcon merger agreement, further delays deal
3
Five-year GALE study data announced
4
AAO 2025: Effect of cryopreserved amniotic membrane after corneal cross-linking in patients with keratoconus
5















































.png)


